ClinicalTrials.gg
CompletedNCT00334880Updated Jul 2, 2009

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

A Phase 3 interventional study of NRP104 in Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity and Attention Deficit Hyperactivity Disorders, sponsored by New River Pharmaceuticals. Completed at 48 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2009-07-02.

Sponsored by New River Pharmaceuticals (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
3rd of 51
420 · median 48
Started
2006
with 2 others
Phase 3
15 of 51
none open now
Registered
3rd of 51
by date
Lead sponsor
6 of 51
New River Pharmaceuticals

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 3rd largest by enrollment, is one of 3 that started in 2006, is one of 15 in phase 3, and was the 3rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD).

Read the detailed description

This study is a randomized, phase III, multi-center, placebo-controlled, parallel-group, forced dose titration in which adult subjects (18-55 years of age inclusive) with ADHD will be randomized to NRP104 (30, 50, or 70 mg) or placebo for four weeks of double-blind evaluation of safety and efficacy.

The study will have three phases: (1) screening and washout; (2) baseline; and (3) 4-week double-blind evaluation of NRP104 and placebo. The double-blind period will include a forced dose titration phase followed by a fixed dose phase. Subjects will be required to visit the site up to 6 times over a 5-8 week period, or longer in cases requiring a 28-day wash out.

Screening and Washout: Subjects will be screened to establish eligibility for study participation. The Screening Visit (Visit 1) may take place over multiple days if needed to accommodate the subject's schedule. Those subjects who meet eligibility requirements will undergo medication washout, if applicable. The length of the ADHD medication washout period will range from 7-28 days.

Baseline: Following medication washout, subjects will return to the clinic for reassessment of eligibility criteria and establishment of baseline measures. The interval between the first day of the Screening Visit (informed consent date) and the Baseline Visit (Visit 2) must not exceed 35 days. Eligible subjects with a baseline ADHD-RS score greater than or equal to 28 (performed using adult DSM-IV prompts) will be randomized to treatment.

Double-blind treatment: Eligible subjects will be randomly assigned (in a 2:2:2:1 ratio of each of the three active doses vs. placebo) to a daily morning dose of NRP104 or placebo for 4 weeks. All NRP104 groups will start at a dose of 30 mg/day. Subjects randomized to 70 mg will be titrated to that dose over a 2-week period; those randomized to 50 mg will be titrated to that dose over a 1-week period; and those randomized to 30 mg will begin dosing on 30 mg per day during week one and will remain on that dose throughout the study. Double-blind assessment of the safety and efficacy of NRP104 will proceed for 4 weeks with weekly clinic visits scheduled for evaluations and medication disbursement.

Follow-up period: Subjects who have completed at least 2 weeks of double-blind participation, will have the option to continue participation in an open-label extension study (Protocol NRP104.304: one-year safety study). Subjects who are not eligible or who choose not to participate in the extension study will continue to be followed for thirty days following their last dose of study drug. A telephone contact (or contact in person) will be initiated by the research site to collect any new or ongoing SAEs and to follow-up on any unresolved or related AEs from the Final Study Visit or Early Termination (ET) Visit (Visit 6). If the Principal Investigator determines AEs are not acceptably resolved, appropriate follow-up should continue until all safety concerns, in the opinion of the Investigator, are resolved.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorders With Hyperactivity
  • Attention Deficit Hyperactivity Disorders

Keywords

  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorders with Hyperactivity
  • Attention Deficit Hyperactivity Disorders
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 18-55 years of age, inclusive.
  • Must be male or non-pregnant female. Females of (FOCP) must use .
  • Must have a medical assessment with no or relevant abnormalities as determined by medical history, PE, clinical and lab evaluation.
  • Must have 12-lead ECGs defined by the following parameters:

    1. /QTcF interval \< 450 msec for males and \< 470 msec for females
    2. Resting heart rate is between 40 and 100 beats per minute
    3. P-R interval \< 200 msec
    4. QRS interval \<110 msec.
  • Meets Fourth Edition; Text Revision (DSM-IV-TR™) criteria for a primary diagnosis of ADHD (diagnostic code 314.00 and 314.01) established by a psychiatric evaluation that reviews DSM-IV-TR™ criteria with at least 6 of the 9 subtype criteria met. The Adult ADHD Clinical Diagnostic Scale (ACDS v1.2) will be utilized as the diagnostic tool.
  • Has a baseline ADHD-RS score greater than or equal to 28 assessed using adult DSM-IV prompts.
  • Understands and is able, willing, and likely to fully comply with the study procedures and restrictions.
  • Has given written to participate in the study in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines and applicable regulations before completing any study procedures.

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the investigator, the subject is significantly underweight [e.g., (BMI) \< 18.5] or morbidly obese.
  • Has any comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorders or severe Axis I disorders including Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations that will contraindicate NRP104 treatment or confound efficacy or safety assessments. Specifically, subjects with mild to moderate forms of Axis I disorders including social phobia and dysthymia may be included while subjects with a lifetime history of psychosis or bipolar disorder will be excluded from participation. Comorbid psychiatric diagnoses will be established by a psychiatric evaluation that includes the Structured Clinical Interview for ™ disorders (SCID-I) interview at the screening visit.
  • Has any concurrent chronic or acute illness or unstable medical condition that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol. Subjects with mental retardation or a severe learning disability are excluded.
  • Has a history of seizure (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder.
  • Has a known cardiac structural abnormality or any other condition that may affect cardiac performance.
  • Has any or laboratory abnormality at Screening or Baseline.
  • Subject has a history of hypertension or has a resting sitting systolic blood pressure > 139mmHg or diastolic blood pressure > 89mmHg.
  • Has used any prohibited medication except for ADHD medications within 30 days of screening visit. Hormonal are acceptable.
  • Has a documented allergy, intolerance, or documented history of non-responsivity to methylphenidate or amphetamine.
  • Currently has (or had a history within the last 6 months of) a drug dependence or substance abuse disorder according to DSM-IV-TR™ criteria (excluding nicotine) as established by a SCID-I at the screening visit.
  • Has a positive urine drug result at Screening (with the exception of subject's current stimulant therapy, if any) or at Baseline.
  • Has taken an drug or taken part in a clinical trial within 30 days prior to Screening.
  • The female subject is pregnant or lactating.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
420 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinician-administered ADHD-rating scale (ADHD-RS) performed using adult DSM-IV prompts

    Time frame: weekly over a period of 4 weeks

Secondary outcomes

  1. The Clinical Global Impression of Improvement (CGI-I)

    Time frame: 4 times over a period of 4 weeks

  2. Self-report of the Pittsburgh Sleep Quality Index (PSQI) measured at Baseline and at the Final Study Visit

    Time frame: twice over a period of 4 weeks

  3. Occurrence of treatment-emergent adverse events and specific evaluation of blood pressure, heart rate, electrocardiogram (ECG), laboratory findings, and physical examination (PE)

    Time frame: 4 weeks

07

Study locations

48 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Research, Inc.
    El Centro, California 92243, United States
  • University of California, Irvine Child Development Center
    Irvine, California 92612, United States
  • Bay Area Research Institute
    LaFayette, California 94549, United States
  • Peninsula Research Associates
    Rolling Hills Estate, California 90274, United States
  • University of California, San Francisco, Dept. of Psychiatry
    San Francisco, California 94143, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80304, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • Psychiatric Medicine Center
    New London, Connecticut 06320, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Miami Research Associates
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Janus Center for Psychiatric Research LLC
    West Palm Beach, Florida 33407, United States
  • Northwest Behavioral Research Center
    Roswell, Georgia 30076, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Johns Hopkins at Green Spring Station
    Lutherville, Maryland 21093, United States
  • Marc Hertzman, MD
    Rockville, Maryland 20852, United States
  • Massachusetts General Hospital
    Cambridge, Massachusetts 02138, United States
  • Summit Research Network (Michigan) Inc.
    Flint, Michigan 48507, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • St Charles Psychiatric Associates-Midwest Research
    St Charles, Missouri 63301, United States
  • Mercy Health Research
    St. Louis, Missouri 63141, United States
  • Center for Psychiatry and Behavioral Medicine
    Las Vegas, Nevada 89128, United States
  • CNS Research Institute (CRI)
    Clementon, New Jersey 08021, United States
  • VA NY Harbor Healthcare System
    New York, New York 10010, United States
  • Duke University ADHD Program
    Durham, North Carolina 27705, United States
  • Richard Weisler and Associates
    Raleigh, North Carolina 27609, United States
  • University Hospitals of Cleveland, Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon 97210-2659, United States
  • CNS Research Institute, P.C.
    Philadelphia, Pennsylvania 19149, United States
  • FutureSearch Trials
    Austin, Texas 78756, United States
  • Claghorn-Lesem Research Clinic
    Bellaire, Texas 77401, United States
  • Bayou City Research
    Houston, Texas 77007, United States
  • Red Oak Psychiatry Associates, P.A.
    Houston, Texas 77090, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • John M. Turnbow, MD, PA
    Lubbock, Texas 79423, United States
  • The Clinical Study Center
    Burlington, Vermont 05401, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Psychiatric Alliance of the Blue Ridge Clinical Research
    Charlottesville, Virginia 22903, United States
  • NeuroScience, Inc.
    Herndon, Virginia 20170, United States
  • Brighton Research Group
    Virginia Beach, Virginia 23452, United States
  • Summit Research Network LLC (Seattle)
    Seattle, Washington 98104, United States
08

References and documents

Publications

  • Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Sep;69(9):1364-73. doi: 10.4088/jcp.v69n0903. Epub 2008 Sep 9. PubMed 19012818 ↗
  • Mattingly GW, Weisler RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Goodman DW. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2013 Jan 29;13:39. doi: 10.1186/1471-244X-13-39. PubMed 23356790 ↗
  • Babcock T, Dirks B, Adeyi B, Scheckner B. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacol Toxicol. 2012 Dec 19;13:18. doi: 10.1186/2050-6511-13-18. PubMed 23254273 ↗
  • Surman CB, Roth T. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. J Clin Psychiatry. 2011 Jul;72(7):903-8. doi: 10.4088/JCP.11m06838. PubMed 21824454 ↗
  • Waxmonsky JG, Waschbusch DA, Glatt SJ, Faraone SV. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. J Clin Psychiatry. 2011 Oct;72(10):1366-75. doi: 10.4088/JCP.10m05979pur. PubMed 21367347 ↗
  • Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2009 Dec;70(12):1652-61. doi: 10.4088/JCP.09m05335pur. PubMed 20141706 ↗
  • Adler LA, Goodman D, Weisler R, Hamdani M, Roth T. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct. 2009 Aug 3;5:34. doi: 10.1186/1744-9081-5-34. PubMed 19650932 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2006
First posted
Jun 8, 2006
Start
May 2006
CompletionActual
Nov 2006
Last update
Jul 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00334880
First posted
Jun 8, 2006
Start date
May 2006
Completion
Nov 2006
Last update
Jul 2, 2009

Study contacts

Joseph Biederman, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion